Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASH: Celgene's pomalidomide shows durable response in late multiple myeloma

This article was originally published in Scrip

Executive Summary

Celgene's pomalidomide appears to produce durable responses in multiple myeloma patients who have failed previous therapies, suggest data from the pivotal Phase III MM-003 presented this week at the American Society of Hematology meeting in Atlanta.

You may also be interested in...

EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

New data from Novo Nordisk supporting its GLP-1 agonist will fortify the firm's new drug applications, strengthen its position in price negotiations and boost its chances of reimbursement.

With VERTIS SITA2 On Board, Merck Eyes Broad Initial Approval For Ertugliflozin

In an interview at the European Association for the Study of Diabetes meeting, Merck exec Sam Engel explains the rationale behind the clinical trial strategy for the SGLT-2 inhibitor ertugliflozin, as it gears up with partner Pfizer for filings by the end of this year.

Highlights from the American Society of Hematology meeting

Datamonitor Healthcare's Aine Slowey takes an in-depth look at the highlights of this week's annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana, focussing on Roche/Biogen Idec's Gazyva, Celgene's Revlimid and Gilead's idelalisib.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts